A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas

Werner Scheithauer; Franz Pfeffel; Gabriela Kornek; A Marczell; Christoph Wiltschke; Martin Funovics

doi:10.1002/1097-0142(19921001)70:7<1864::aid-cncr2820700709>3.0.co;2-d

Abstract

Although the combination of 5-FU, LV, and recombinant alpha-2b-IFN in patients with advanced pancreatic adenocarcinoma has some activity and generally was well tolerated, the observed response rate and median survival were not superior to 5-FU monotherapy.

Keywords

MedicineFluorouracilAlpha interferonPancreasRecombinant DNAAlpha (finance)AdenocarcinomaInterferon alfaInternal medicineGastroenterologyOncologyInterferonChemotherapySurgeryVirologyCancerBiochemistry

Affiliated Institutions

Related Publications

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris , Malcolm J. Moore , John Sahl Andersen +11 more

PURPOSE Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a sign...

1997 Journal of Clinical Oncology 5830 citations

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

G. Stathopoulos , K. Syrigos , Gerasimos Aravantinos +11 more

Our purpose was to determine the response rate and median and overall survival of gemcitabine as monotherapy versus gemcitabine plus irinotecan in advanced or metastatic pancrea...

2006 British Journal of Cancer 196 citations

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

Justin S. Waters , A. Norman , David Cunningham +12 more

We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF re...

1999 British Journal of Cancer 278 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Publication Info

Year: 1992
Type: article
Volume: 70
Issue: 7
Pages: 1864-1866
Citations: 35
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Werner Scheithauer, 
                                
                                    Franz Pfeffel, 
                                
                                    Gabriela Kornek
                                
                                et al.
                            
                            (1992). 
                            A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. 
                            Cancer
                            , 70
                            (7)
                            , 1864-1866.
                            https://doi.org/10.1002/1097-0142(19921001)70:7<1864::aid-cncr2820700709>3.0.co;2-d
                        

Identifiers

DOI: 10.1002/1097-0142(19921001)70:7<1864::aid-cncr2820700709>3.0.co;2-d